The FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with advanced multiple myeloma that has returned or stopped responding to prior therapy. The clearance marks a new milestone for BMS as it tries to sustain its myeloma franchise amid intensifying competition.